Edwards Lifesciences (EW) Net Margin (2009 - 2025)

Edwards Lifesciences' Net Margin history runs 17 years deep, the most recent figure standing at 1.72% for Q4 2025.

• On a quarterly basis, Net Margin fell 112.0% year-over-year to 1.72% in Q4 2025; TTM through Mar 2026 was 0.33%, a 4930.0% decrease from a year earlier, with the FY2025 full-year figure at 0.22%, down 5077.0% from the prior year.
• Net Margin grew to 1.72% in Q4 2025 per EW's latest filing, from 0.13% in the prior quarter.
• Across five years, Net Margin topped out at 199.89% in Q3 2024 and bottomed at 0.51% in Q1 2025.
• The 5-year median for Net Margin is 14.72% (2023), against an average of 26.76%.
• Across the five-year window, Net Margin jumped 19596 bps in 2024 and sank 20002 bps in 2025, its largest moves.
• Year by year, Net Margin stood at 25.22% in 2021, then surged by 268 bps to 92.67% in 2022, then plunged by 97 bps to 2.89% in 2023, then fell by 2 bps to 2.84% in 2024, then plunged by 39 bps to 1.72% in 2025.
• Per Business Quant, the three latest EW Net Margin figures stand at 1.72% (Q4 2025), 0.13% (Q3 2025), and 0.29% (Q2 2025).